Around 10% of Deaths from Coronary Stenting, Balloon Angioplasty Are Preventable | Complications During Procedures Only Contributed to Death in About 20% of Cases

Each year more than 500,000 Americans undergo percutaneous coronary intervention, or PCI, a minimally invasive procedure to unclog the arteries that feed the heart.

While PCI, which includes both angioplasty and stenting, is one of the most common operations in the world, it does carry a small (about 1-2%) but significant risk of death. Around 10% of all deaths following percutaneous coronary intervention are potentially preventable, a study led by Michigan Medicine finds.

The results are published in PLOS ONE.

“Deaths in the hospital after PCI are rare and mostly occur in patients who arrive after a heart attack, especially if their cases involve shock,” said senior author Hitinder Gurm, M.B.B.S., chief medical officer at University of Michigan Health and medical director of the Blue Cross Blue Shield of Michigan Cardiovascular Consortium, or BMC2.

“The vast majority of deaths after PCI are unpreventable and related to patients’ underlying conditions for which they are undergoing the procedure. This is a stark change from the 1990s when the majority of deaths were traceable to procedural complications.”

The research team analyzed deaths after PCI occurring at 39 Michigan hospitals participating in BMC2 between 2012 and 2014. These hospitals use procedural and outcome data to inform quality projects to improve care and patient outcomes.

Procedural complications contributed to 20% of the nearly 1,200 deaths reported during the study period. Just over one quarter of the patients who died were considered low risk, meaning a PCI-related mortality risk score estimated they had a 95% or greater chance of survival.

Of the deaths that were considered preventable, 10.1% in total, angioplasty and stenting was deemed to be of low value and potentially avoidable nearly one third of the time.

Researchers say the data suggests a need to focus on optimizing appropriateness of PCI to ensure providers are limiting rare, preventable deaths from this common procedure.

“Our data may help inform how cath labs conduct morbidity and mortality conferences, a common quality improvement practice at many hospitals, by focusing on patients with low predicted risk of mortality who subsequently experienced an adverse event,” said first author Francesco Moroni, M.D., fellow at the Robert M. Berne Cardiovascular Research Center at University of Virginia.

“Such a focus may be an effective method of identifying on periprocedural practices, as opposed to patient-related factors, that may have played a role in a patient’s adverse outcome.”

Additional Authors

Include Milan Seth, M.Sc., of University of Michigan, Francesco Moroni, M.D., of University of Virigina and Università Milano-Bicocca, Hameem U. Changezi, M.D., of McLaren Flint Cardiology, Milind Karve, M.D., of Sparrow Health, Dilip S. Arora, M.D., of Corewell Health South Lakeland, Manoj Sharma, M.D., M.B.A., of Covenant HealthCare, Elizabth Pielsticker, M.D., of Henry Ford-Jackson, Aaron D. Berman, M.D., of Corewell Health William Beaumont University Hospital, Daniel Lee, M.D., of McLaren Bay Heart and Vascular, M. Imran Qureshi, M.D., of DMC Sinai Grace Hospital, and Lorenzo Azzalini, M.D., Ph.D., M.Sc., of Unversity of Washington.

Funding

Support for BMC2 is provided by Blue Cross and Blue Shield of Michigan and Blue Care Network as part of the BCBSM Value Partnerships program.

Disclosure

Although Blue Cross Blue Shield of Michigan and BMC2 work collaboratively, the opinions, beliefs and viewpoints expressed by the author do not necessarily reflect the opinions, beliefs, and viewpoints of BCBSM or any of its employees.

Citation: “Cause and preventability of in-hospital mortality after PCI: a statewide root-cause analysis of 1,163 deaths,” PLOS ONE. DOI: 10.1371/journal.pone.0297596

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version